Point72 Asset Management
FDMT icon

Point72 Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Point72 Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,539,860
Closed -$11.5M – 4005
2025
Q4 		$11.5M Buy
+1,539,860
New +$15.6M 0.01% 1265
2024
Q4 		– Sell
-15,341
Closed -$166K – 2187
2024
Q3 		$166K Buy
+15,341
New +$255K ﹤0.01% 1821
2024
Q1 		– Sell
-416,020
Closed -$8.43M – 2314
2023
Q4 		$8.43M Sell
416,020
-37,356
-8% -$491K 0.02% 740
2023
Q3 		$5.77M Buy
453,376
+82,489
+22% +$1.38M 0.02% 840
2023
Q2 		$6.7M Buy
370,887
+161,987
+78% +$2.98M 0.02% 718
2023
Q1 		$3.59M Buy
208,900
+69,600
+50% +$1.35M 0.01% 855
2022
Q4 		$3.09M Sell
139,300
-159,700
-53% -$2.47M 0.01% 861
2022
Q3 		$2.4M Buy
+299,000
New +$2.71M 0.01% 888

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management's FDMT Position: Q1 2026 in Review

Point72 Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 1,539,860 shares — an estimated $11.5M sold.

Point72 Asset Management first reported a position in FDMT in Q3 2022 and held it in 8 quarters. The position peaked at $11.5M in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Point72 Asset Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,539,860 4D Molecular Therapeutics shares in Q1 2026, an estimated $11.5M.
  • Point72 Asset Management first reported a position in 4D Molecular Therapeutics in Q3 2022 and held it in 8 quarters.
  • Point72 Asset Management's 4D Molecular Therapeutics position peaked at $11.5M in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.